Connect Biopharma Holdings Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CNTB | ALDX | EDSA | QTTB | ACET | RNTX | |
|---|---|---|---|---|---|---|
| Market cap | 57.04M | 54.64M | 39.72M | 260.19M | 51.77M | 67.71M |
| P/E (TTM) | — | — | — | 2.8 | — | — |
| Forward P/E | -1.3 | -3.3 | — | -8.6 | -1.4 | — |
| Price/book | 2.1 | 1.4 | 71.7 | 2.0 | 0.5 | 6.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −52.20% | −83.03% | +38.19% | +111.14% | −64.00% | −39.85% |
| Today | +4.10% | −1.15% | −16.24% | +4.80% | −1.43% | −1.15% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CNTB news ›Connect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as Outperform by Leerink Partners
Connect Biopharma (NASDAQ:CNTB - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at Leerink Partners in a report issued on Monday, Benzinga reports. They presently have a $4.00 price target on the…
Connect Biopharma: Leonard reports 6.77% stake
A holder reports sole voting power over 400,000 Connect Biopharma (CNTB) shares, plus shared ownership. Stock Titan - [SCHEDULE 13G] Connect Biopharma Holdings Ltd Passive Investment Disclosure (>5%) Connect Biopharma: Leonard reports…
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met…
Connect Biopharma (NASDAQ:CNTB) Given Buy Rating at HC Wainwright
Connect Biopharma (NASDAQ:CNTB - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. Get Our Latest Analysis on Connect…
Connect Biopharma director receives 5,000-share grant
Kleanthis Gabriel Xanthopoulos held 91,554 shares directly after the September 30 grant. The fully vested award covered third-quarter director service. - [Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity Connect Biopharma…
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-30
Seeking Alpha The following slide deck was published by Connect Biopharma Holdings Limited in conjunction with this event.
BTIG cuts Connect Biopharma stock price target on trial timeline By Investing.com
Wall Street gives up gains just before close, posts a slight loss for September Oil rises for September, Brent jumps 14% as Middle East conflict drags on Gold prices to snap two-month winning streak with a September loss of more than 6%…
BTIG maintains Buy rating on Connect Biopharma Hldgs, $5 price target
BTIG maintained their Buy rating on Connect Biopharma Hldgs's stock with a price target of $5.00. The price target implies an upside of 404.0% from the Sep 29 close of $0.99. Key takeaways from the analyst note Favorable Safety Profile:…
Connect Biopharma Surges After Positive COPD Trial Readout | CNTB Stock News
Connect Biopharma Holdings Limited (CNTB) is up 34.3% today. Here is some analysis on what might have caused this price movement.Analysis: The most likely driver is positive preliminary topline data from the company’s Phase 2 Seabreeze…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketbeat.com3
-
stocktitan.net2
-
tradingview.com2
-
in.investing.com1
-
quiverquant.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.